67 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
13 May 24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:15am
or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety … in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials … that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation
424B5
6q6wi3dcy wv
26 Jan 24
Prospectus supplement for primary offering
4:08pm
424B5
ijoip1d2hx9sz8d5qb
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
EX-99.1
e7y4ukdm
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.2
aynfaw5 rsb
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
kfr508ulomxn1svrb
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.2
qk5ql41m hk
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
31ma twv75vz1
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
425
m6j8 7fpent
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
u4pl44b j7yuhrxvm
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
u50gl q800lqhc
15 Sep 23
Prospectus supplement
6:31am
425
ga1ib
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
8t28pnig
13 Sep 23
Regulation FD Disclosure
9:13am